Advicenne S.A. (EPA:ALDVI)

France · Delayed Price · Currency is EUR

0.6560

+0.0050 (0.77%)

Nov 12, 2026, 10:28 AM CET

Market Cap	9.54M -58.8%
Revenue (ttm)	10.74M +82.1%
Net Income	43.00K
EPS	n/a
Shares Out	14.55M
PE Ratio	220.25
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,289
Open	0.6540
Previous Close	0.6510
Day's Range	0.6520 - 0.6790
52-Week Range	0.6090 - 2.3500
Beta	0.84
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 18, 2026

About Advicenne

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Par... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2007

Employees 11

Stock Exchange Euronext Paris

Ticker Symbol ALDVI

Full Company Profile

Financial Performance

In 2025, Advicenne's revenue was 6.40 million, an increase of 21.56% compared to the previous year's 5.27 million. Losses were -9.53 million, 47.5% more than in 2024.

Financial Statements